Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Colchicine as a Novel Therapy for Suppressing Chemokine Production in Patients With an Acute Coronary Syndrome: A Pilot Study.

Tucker B, Kurup R, Barraclough J, Henriquez R, Cartland S, Arnott C, Misra A, Martínez G, Kavurma M, Patel S.

Clin Ther. 2019 Aug 10. pii: S0149-2918(19)30358-3. doi: 10.1016/j.clinthera.2019.07.015. [Epub ahead of print]

PMID:
31409556
2.

Repetitive hypoglycemia reduces activation of glucose-responsive neurons in C1 and C3 medullary brain regions to subsequent hypoglycemia.

Kakall ZM, Kavurma MM, Cohen EM, Howe PR, Nedoboy PE, Pilowsky PM.

Am J Physiol Endocrinol Metab. 2019 Aug 1;317(2):E388-E398. doi: 10.1152/ajpendo.00051.2019. Epub 2019 Apr 23.

3.

Tumour necrosis factor superfamily members in ischaemic vascular diseases.

Nash M, McGrath JP, Cartland SP, Patel S, Kavurma MM.

Cardiovasc Res. 2019 Mar 15;115(4):713-720. doi: 10.1093/cvr/cvz042.

PMID:
30816914
4.

TRAIL-Expressing Monocyte/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis.

Cartland SP, Genner SW, Martínez GJ, Robertson S, Kockx M, Lin RC, O'Sullivan JF, Koay YC, Manuneedhi Cholan P, Kebede MA, Murphy AJ, Masters S, Bennett MR, Jessup W, Kritharides L, Geczy C, Patel S, Kavurma MM.

iScience. 2019 Feb 22;12:41-52. doi: 10.1016/j.isci.2018.12.037. Epub 2019 Jan 4.

5.

Microglia in the RVLM of SHR have reduced P2Y12R and CX3CR1 expression, shorter processes, and lower cell density.

Cohen EM, Mohammed S, Kavurma M, Nedoboy PE, Cartland S, Farnham MMJ, Pilowsky PM.

Auton Neurosci. 2019 Jan;216:9-16. doi: 10.1016/j.autneu.2018.12.002. Epub 2018 Dec 8.

PMID:
30598122
6.

TRAIL protects against endothelial dysfunction in vivo and inhibits angiotensin-II-induced oxidative stress in vascular endothelial cells in vitro.

Manuneedhi Cholan P, Cartland SP, Dang L, Rayner BS, Patel S, Thomas SR, Kavurma MM.

Free Radic Biol Med. 2018 Oct;126:341-349. doi: 10.1016/j.freeradbiomed.2018.08.031. Epub 2018 Aug 27.

PMID:
30165101
7.

NADPH Oxidases, Angiogenesis, and Peripheral Artery Disease.

Manuneedhi Cholan P, Cartland SP, Kavurma MM.

Antioxidants (Basel). 2017 Jul 12;6(3). pii: E56. doi: 10.3390/antiox6030056. Review.

8.

Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice.

Cartland SP, Harith HH, Genner SW, Dang L, Cogger VC, Vellozzi M, Di Bartolo BA, Thomas SR, Adams LA, Kavurma MM.

Sci Rep. 2017 May 15;7(1):1898. doi: 10.1038/s41598-017-01721-4.

9.

The walking dead: macrophage inflammation and death in atherosclerosis.

Kavurma MM, Rayner KJ, Karunakaran D.

Curr Opin Lipidol. 2017 Apr;28(2):91-98. doi: 10.1097/MOL.0000000000000394. Review.

10.

Comparative Evaluation of TRAIL, FGF-2 and VEGF-A-Induced Angiogenesis In Vitro and In Vivo.

Cartland SP, Genner SW, Zahoor A, Kavurma MM.

Int J Mol Sci. 2016 Dec 2;17(12). pii: E2025.

11.

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms.

Di Bartolo BA, Cartland SP, Prado-Lourenco L, Griffith TS, Gentile C, Ravindran J, Azahri NS, Thai T, Yeung AW, Thomas SR, Kavurma MM.

J Am Heart Assoc. 2015 Nov 16;4(11). pii: e002527. doi: 10.1161/JAHA.115.002527.

12.

Insulin promotes vascular smooth muscle cell proliferation and apoptosis via differential regulation of tumor necrosis factor-related apoptosis-inducing ligand.

Harith HH, Di Bartolo BA, Cartland SP, Genner S, Kavurma MM.

J Diabetes. 2016 Jul;8(4):568-78. doi: 10.1111/1753-0407.12339. Epub 2015 Dec 7.

PMID:
26333348
13.

TRAIL deficiency contributes to diabetic nephropathy in fat-fed ApoE-/- mice.

Cartland SP, Erlich JH, Kavurma MM.

PLoS One. 2014 Mar 25;9(3):e92952. doi: 10.1371/journal.pone.0092952. eCollection 2014.

14.

Regulation and function of Rankl in arterial calcification.

Di Bartolo BA, Kavurma MM.

Curr Pharm Des. 2014;20(37):5853-61.

PMID:
24533935
15.

TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL.

Di Bartolo BA, Cartland SP, Harith HH, Bobryshev YV, Schoppet M, Kavurma MM.

PLoS One. 2013 Sep 5;8(9):e74211. doi: 10.1371/journal.pone.0074211. eCollection 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/9732ca63-7532-4b92-8d6e-65c0863f25aa.

16.

On the TRAIL of obesity and diabetes.

Harith HH, Morris MJ, Kavurma MM.

Trends Endocrinol Metab. 2013 Nov;24(11):578-87. doi: 10.1016/j.tem.2013.07.001. Epub 2013 Aug 12. Review.

PMID:
23948591
17.

Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Azahri NS, Kavurma MM.

Cell Mol Life Sci. 2013 Oct;70(19):3617-29. doi: 10.1007/s00018-013-1264-x. Epub 2013 Jan 18. Review.

PMID:
23329170
18.

Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration.

Azahri NS, Di Bartolo BA, Khachigian LM, Kavurma MM.

J Cell Biochem. 2012 Aug;113(8):2597-606. doi: 10.1002/jcb.24135.

PMID:
22415975
19.

TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe ⁻/⁻ mice.

Di Bartolo BA, Chan J, Bennett MR, Cartland S, Bao S, Tuch BE, Kavurma MM.

Diabetologia. 2011 Dec;54(12):3157-67. doi: 10.1007/s00125-011-2308-0. Epub 2011 Oct 1.

PMID:
21965021
20.

Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification.

Di Bartolo BA, Schoppet M, Mattar MZ, Rachner TD, Shanahan CM, Kavurma MM.

Cardiovasc Res. 2011 Aug 1;91(3):537-45. doi: 10.1093/cvr/cvr084. Epub 2011 Mar 29.

PMID:
21447702

Supplemental Content

Loading ...
Support Center